1.
June 24, 2017 | Products & Services | 621
Products & Services
What worms?
Zoetis is encouraging sheep farmers
to investigate what species of parasitic
worms are infecting their sheep this
year after farms involved in its Parasite
Watch scheme reported infections
with different species simultaneously.
The company is advising farmers to
find out whether their sheep are being
challenged by Nematodirus species
only or other species of worms as well
to ensure that they use an appropriate
product when treating them.
Dave Armstrong, a vet with Zoetis,
said that spring had brought a mixed
picture of worm challenge this year,
with high challenge on some farms
and low challenge on others.
‘Nematodirus seems to have been
less of an issue on farms in the south,
which could be due to a number of
reasons,’ he said. ‘It could be that
farms lambed earlier down south so
missed the peak of the challenge, or a
microclimate element could be playing
a part. The mixed burden of worms
has shocked a few people and altered
treatment strategies.’
Zoetis, Walton Oaks, Dorking Road,
Tadworth, Surrey KT20 7NF, telephone
0845 300 8034. www.zoetis.co.uk
Regenerative therapy for canine joint conditions
Crown Vets Referrals in Inverness is working
with Lipogems Canine to offer a novel treat-
ment for dogs that ‘harnesses the regenera-
tive power of the body’s stem cells to reduce
joint inflammation’ and has ‘significant
potential to repair damaged cartilage and soft
tissue in and around inflamed joints’.
The treatment involves the collection
of adipose tissue using a vacuum syringe
from around the flank of a dog under anaes-
thetic. The tissue is then ‘microfragmented’
using a non-enzymatic mechanical process
in a closed system and disposable device to
harvest pericytes. Pericytes gradually con-
vert into activated mesenchymal stem cells
(MSCs), which are able to differentiate into
a variety of cell types, including osteoblasts,
chondrocytes, myocytes and adipocytes.
The harvested cells are injected back into
the patient to treat an injured area, particu-
Norbrook Laboratories has added Betafuse
gel to its range of products for companion
animals. The gel, a steroid-based antibiotic
preparation, is indicated for the treatment of
acute surface pyoderma in dogs, such as acute
moist dermatitis (‘hot spots’) and intertrigo
(skin fold dermatitis).
The product, which contains fusidic
acid (5 mg/g) and betamethasone (1 mg/g), is
This section aims to help keep readers up to date with some of the products
and services available to the veterinary profession. It is compiled using
information and images provided by manufacturers, suppliers and service
providers. Inclusion of material does not imply endorsement by Veterinary
Record and anyone thinking about buying or making use of any of the
products or services mentioned should do their own research beforehand.
Manufacturers, suppliers and service providers who wish to submit material
for possible inclusion in Products Services are encouraged to do so, and
should send any news releases to products@bva-edit.co.uk
larly cartilage and soft tissue damage around
inflamed joints.
The whole procedure can be completed
in less than 40 minutes. Lipogems Canine
says that healing can be promoted as early as
10 days after treatment and that there is lit-
tle requirement for drug use. It adds that the
main structural and morphological adipose
unit, the adipose niche, is maintained after the
processing of the adipose tissue, and protects
the MSCs, acting as a local scaffold to main-
tain regenerative activity for many months.
The company says the use of Lipogems
is best suited to arthritic joints where tradi-
tional therapies have failed to control pain
and joint replacement is not an option.
Crown Vets Referrals, 58 Argyle Street,
Inverness IV2 3BB, telephone 01463
237000. www.crownvetsreferrals.co.uk.
www.lipogemscanine.com
Treating surface pyoderma in dogs
available in 15 g and 30 g sizes in what the
company describes as a ‘unique polyfoil tube,
to reduce the likelihood of splitting and loss
of product during use’.
Richard Palmer, global head of sales
and marketing at Norbrook, commented:
‘Betafuse is particularly exciting for us as we
have improved the packaging and we have
extended the “in use” shelf life to eight weeks
in comparison to six weeks for the phar-
maceutically equivalent pioneer.’
A leaflet for owners giving details
of how to apply Betafuse effectively is
available from Norbrook territory man-
agers or from the company’s website.
Norbrook Laboratories, Carnbane
Industrial Estate, Newry, Northern
Ireland BT35 6QQ, telephone 028 3026
4435, www.norbrook.com
D
R
A
F T